TABLE 2.
HBV RT substitutions at T184, S202, or M250
| Substitution group | Substitutions (no. of patients)a | LVDr backbone substitutions |
|---|---|---|
| Baseline T184, S202, or M250 substitutionb | T184A (2), I (2), S (13), A/S (1) | L180M, M204I/V, or M204I |
| S202C (1), G (2) | L180M, M204I/V | |
| M250I (1), L (4) | L180M, M204I/V, or M204I | |
| T184A and S202G (1) | L180M, M204V | |
| Emerging T184, S202, or M250 substitution during ETV therapy | T184A (1), I (2), S (1), A/S (1), L/S (1), I/L (1), F/L/M (1) | L180M, M204I/V |
| S202G (12) | L180M, M204I/V | |
| M250L (1) | M204I | |
| T184A/S and S202G (1), T184A and S202G (1) | L180M, M204V |
a
The sequences of the ETVr- and LVDr-encoding positions most often included mixtures with WT residues, but only the substitutions are shown. Numbers in parentheses indicate the number of patients whose isolates were found to have the indicated substitution.
b
Baseline patients were those subsequently randomized to any treatment arm; only 10 of the 27 patients were randomized to the 1.0-mg ETV treatment arm. Emerging substitutions were those in the 1.0-mg ETV treatment arm.